"In this sense, Bavituximab is rather similar to HEB’s Ampligen, another drug that was claimed to be an all-purpose treatment for widely disparate diseases."
Thanks for the reply, Dew. I don't know anything about Ampligen, but Baci's claim to generality involves a phenomenon common to cancers and viruses: flipping a normal cell's PS from the inside to the outside of the cell wall. They appear to have good anecdotal evidence of results (their one-arm trials) and may have good hard evidence of efficacy in this 2d line NSCLC trial. We should know soon.
Market Data 
Markets 
AI
